Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - Results from the ProGERD study

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 6, 2007, Pages 715-722

  Nocon, M ^a   Labenz, J ^b   Jaspersen, D ^c   Meyer Sabellek, W ^d,e   Stolte, M ^f   Lind, T ^d,e   Malfertheiner, P ^g   Willich, S N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Ev Jung Stilling Krankenhaus   (Germany)

^c KLINIKUM FULDA   (Germany)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

^f INSTITUTE OF PATHOLOGY   (Germany)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REFLUX ESOPHAGITIS;

COHORT STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PROTON PUMPS;

EID: 33847064154     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03249.x     Document Type: Article

References (30)

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma. N Engl J Med 1999; 340: 825-31.
3. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-an analysis based on the ProG-ERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76.
4. Agreus L, Borgquist L. The cost of gastrooesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002; 20: 347-55.
5. Willich SN, Nocon M, Kulig M, Jaspersen D, Labenz J, Meyer-Sabellek W, et al. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006; 23: 371-6.
6. Nocon M, Labenz J, Willich SN. Lifestyle factors and symptoms of gastrooesophageal reflux - a population-based study. Alimentary Pharmacology and Therapeutics 2006; 23: 169-74.
7. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut 2004; 53: 1730-5.
8. Kinoshita Y. Review article: treatment for gastro-oesophageal reflux disease - lifestyle advice and medication. Aliment Pharmacol Ther 2004; 20(Suppl. 8): 19-23.
9. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 2692-7.
10. Fock KM, Talley N, Hunt R, Fass R, Nandurkar S, Lam SK, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357-67.
11. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44: 1S-6.
12. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 18: CD003245.
13. Sjostedt S, Befrits R, Sylvan A, Harthon C, Jorgensen L, Carling L, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 183-91.
14. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
15. Hansen AN, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, et al. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005; 59: 655-64.
16. Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther 2005; 22(Suppl. 3): 39-44.
17. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002; 20: 267-77.
18. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics 2002; 20: 565-76.
19. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 451-3.
20. Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long Clin Gastroenterol Hepatol 2005; 3: 208-15.
21. Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-9.
22. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005; 54: 746-51.
23. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7.
24. Nocon M, Kulig M, Leodolter A, Malfertheiner P, Willich SN. Validation of the Reflux Disease Questionnaire for a German population. Eur J Gastroenterol Hepatol 2005; 17: 229-33.
25. Bytzer P, Blum A, De HD, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-8.
26. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63.
27. Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502-7.
28. Newcastle Guideline Development and Research Unit. Dyspepsia: Management of Dyspepsia in Adults in Primary Care. London: National Institute for Clinical Excellence, 2004.
29. Hansen AN, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, et al. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005; 59: 655-64.
30. Lee TJ, Fennerty MB, Howden CW. Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease Aliment Pharmacol Ther 2004; 20: 1241-51.